drugset / Trial / NCT04368819
Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms
Phase 2/3
Unknown
40 enrolled
Ministry of Health, Brazil
Fundação de Amparo à Pesquisa do Estado de São Paulo · collabInCor Heart Institute · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Despite numerous advances in medical treatment and revascularization procedures for the treatment of patients with stable angina, debilitating symptoms that are unresponsive to conventional therapy may occur in patients unsuitable for revascularization, a condition known as refractory angina. Allopurinol, a methylxanthine oxidase inhibitor, is widely used in the treatment of gout and asymptomatic hyperuricemia. On the other hand, the anti-ischemic effects of allopurinol have been the subject of increasing interest. Therefore, the investigators will study the safety and efficacy of allopurinol in alleviating ischemic symptoms in patients with refractory angina already on optimal medical therapy.
Timeline
- Start
- 2021-03-03
- Primary completion
- 2021-09-30
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Allopurinol | Small molecule | 300 mg | Oral |
Indications
No indication recorded.